

C 1 5. (Amended) A vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least one inactivated or attenuated *Mycoplasma bovis* biotype and a pharmaceutically acceptable excipient, wherein at least one of the inactivated or attenuated *Mycoplasma bovis* biotypes is selected from the group consisting of biotype A, biotype B and biotype C.

Please add the following new claims:

SUB C 2 22. (New) The vaccine of claim 21, comprising at least two inactivated *Mycoplasma bovis* biotypes and a pharmaceutically acceptable excipient, wherein the vaccine is protective against *Mycoplasma bovis* mastitis in a bovine species following systemic administration.

SLB C 3 23. (New) The vaccine of claim 21, wherein the vaccine does not include saponin.

SLB C 3 24. (New) The vaccine of claim 21, wherein the vaccine includes at least one inactivated *Mycoplasma bovis* biotype selected from the group consisting of biotype A, biotype B and biotype C.

B 25. (New) The vaccine of claim 1, comprising at least two inactivated or attenuated *Mycoplasma bovis* biotypes and a pharmaceutically acceptable excipient.

26. (New) The vaccine of claim 25, wherein at least two of the at least two inactivated or attenuated *Mycoplasma bovis* biotypes can be distinguished from one another by PCR fingerprinting.